German biotech company Morphosys said that to test a new drug for advanced treatment of advanced blood cancer will be recruited more patients. Previous trials of this drug have shown promising results.
The Independent Data Monitoring Committee recommended to increase the number of patients to 450. Currently, 330 people are taking part in the study. In the current study B-MIND tafasitamab drug tested as a drug in relapsed or refractory diffuse large B-cell lymphoma.
The company said that the data on the effectiveness of tafasitamaba that led to the approval of the Committee, were not transferred Morphosys. Shares of the company rose by 10%.
The company creates a sales team in the United States in anticipation of the launch tafasitamaba, formerly known as MOR208, next year.
Recently Morphosys failed during the development of an experimental treatment of atopic dermatitis, which analysts had high hopes.